Loading...
•
Jun 30, 2023
Sight Sciences Q2 2023 Earnings Report
Reported financial results for the second quarter and reaffirmed guidance for full year 2023.
Key Takeaways
Sight Sciences reported a record second quarter revenue of $23.5 million, a 36% increase compared to the prior year period. The company achieved a gross margin of 85.6% and saw a decrease in operating expenses. They also reaffirmed their full-year revenue guidance of $89.0 million to $94.0 million.
Generated record second quarter 2023 total revenue of $23.5 million, an increase of 36% compared to the prior year period.
Achieved total gross margin of 85.6% in the second quarter of 2023 compared to 84.1% in the prior year period.
The SAHARA randomized controlled clinical trial successfully met its primary objective signs endpoint at six months.
Procedures enabled by the OMNI® Surgical System technology were categorized as medically necessary and covered by Cigna Healthcare effective June 15, 2023, expanding access to OMNI for close to 15 million covered lives.
Revenue by Segment
Forward Guidance
Sight Sciences reaffirms revenue guidance expectations for the full year 2023 of $89.0 million to $94.0 million, which represents growth of approximately 25% to 32% compared to 2022. The Company reaffirms its expectation for average adjusted operating expenses on a quarterly basis of approximately $30.5 million for the full year 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...